Shane Schaffer

Chairman and CEO, Cingulate Inc. (biotech industry)

Shane Schaffer is the co-founder, chairman, and CEO of Cingulate Therapeutics, a Phase 3 clinical-stage biopharmaceutical company based in Kansas City, Kansas. The company specializes in the development and management of several branded next-generation pharmaceutical products, with a strong focus on Attention Deficit/Hyperactivity Disorders (ADHD) and expanding into other therapeutic areas like anxiety disorders and insomnia.

Expertise in Pharmaceuticals

With 25 years of experience in the pharmaceutical industry, he is an expert in drug development and commercialization. An entrepreneurial spirit and a comprehensive understanding of various business operations, including product launches, brand planning, joint venture brand management, life cycle management, and market development, characterize his leadership. These skills have made him a recognized figure in the biopharmaceutical and marketing sectors.

Educational Background

He completed his doctoral degree in Pharmacy at the University of Kansas in 1999 and pursued a post-doctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy. During his fellowship, he worked at Pfizer Worldwide Marketing and Morris Plains, enhancing his expertise in the field.

Pfizer Worldwide Marketing, New York, NY

While at Pfizer, he served as a Marketing Manager, developing pre-launch strategies and initiating the Global Communications Intranet to bolster communication between medical and marketing teams. He also played a key role in creating and implementing the Pfizer Medical and Academic Partnership in Pain Management.

Morris Plains, New Jersey

At Morris Plains, he took on the roles of project manager and external research manager. His responsibilities included leading advanced sales training, managing development, and overseeing the initiation of Phase IV Medical Research across all marketed brands.

Professional Career

He has held several managerial positions at Pfizer, Novartis, and Sanofi. His strategic acumen has helped develop and commercialize several billion-dollar brands.

Novartis Pharmaceuticals Corporation

At Novartis, he was appointed Product Manager for the Ritalin® LA / Focalin™ segments. He successfully launched Ritalin® LA and Focalin, rapidly achieving significant market penetration and product awareness after their launches. His efforts were recognized with multiple awards, including the Novartis Business Excellence Award.

Sanofi-Aventis

His time at Sanofi-Aventis was marked by significant contributions to managing brands like Avapro and Avalide during their joint venture with Bristol-Myers Squibb. His roles included managing Professional Promotion and Care Marketing Strategy. He was also instrumental in developing the Avalide Promotional Campaign.

Entrepreneurial Ventures

Post Sanofi-Aventis, he joined M|C Communications in Boston as a consultant, leading business development for several major pharmaceutical companies. In 2009, he founded Sabre Scientific Solutions, LLC, providing consulting services to pharmaceutical and biotechnology companies, focusing on commercial, clinical, LCM, product launch, and leadership consulting.

Cingulate Therapeutics LLC

His passion for addressing ADHD and anxiety disorders led him to establish Cingulate Therapeutics LLC in 2013. Under his leadership, the company has advanced its primary drug CTx-1301 to phase 3 trials and is preparing for an FDA new drug application by mid-2025.

Philanthropic Efforts

Beyond his corporate responsibilities, he is deeply involved in philanthropy, particularly with the Folds of Honor Charity, which supports the education of children affected by the loss or disability of their military parents.